$434 Million is the total value of VHCP Management, LLC's 26 reported holdings in Q1 2015. The portfolio turnover from Q4 2014 to Q1 2015 was 25.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| JUNO | Juno Therapeutics Inc | $96,955,000 | +30.4% | 1,749,999 | 0.0% | 22.32% | +9.2% | |
| ANAC | Anacor Pharmaceuticals Inc | $68,175,000 | +79.4% | 1,178,474 | 0.0% | 15.70% | +50.1% | |
| AAVL | Avalanche Biotechnologies Inc | $56,029,000 | -23.3% | 1,382,735 | 0.0% | 12.90% | -35.8% | |
| DBV Technologies | $29,572,000 | -14.2% | 693,810 | 0.0% | 6.81% | -28.2% | ||
| GWPH | GW Pharmaceuticals | $28,419,000 | +34.6% | 311,853 | 0.0% | 6.54% | +12.7% | |
| CHRS | Coherus Biosciences Inc | $26,018,000 | +99.1% | 870,269 | 0.0% | 5.99% | +66.6% | |
| ZFGN | Zafgen Inc | $21,448,000 | +28.4% | 541,480 | 0.0% | 4.94% | +7.5% | |
| DYAX | Dyax Corp | $16,766,000 | +19.2% | 1,000,659 | 0.0% | 3.86% | -0.3% | |
| HRTX | Heron Therapeutics Inc | $15,943,000 | +44.6% | 1,095,734 | 0.0% | 3.67% | +21.1% | |
| BCRX | BioCryst Pharmaceuticals Inc | $15,752,000 | -25.7% | 1,744,356 | 0.0% | 3.63% | -37.8% | |
| ASND | New | Ascendis Pharma A/S | $12,911,000 | – | 811,152 | +100.0% | 2.97% | – |
| FLML | Flamel Technologies S.A. | $8,990,000 | +5.0% | 500,000 | 0.0% | 2.07% | -12.1% | |
| ADHD | New | Alcobra Ltd | $8,446,000 | – | 1,500,000 | +100.0% | 1.94% | – |
| STML | Buy | Stemline Therapeutics Inc | $6,532,000 | +7.4% | 451,400 | +26.7% | 1.50% | -10.1% |
| Buy | Cynapsus Therapeutics Inc | $5,121,000 | +250.0% | 5,878,855 | +282.6% | 1.18% | +193.3% | |
| TXMD | TherapeuticsMD Inc | $5,121,000 | +35.9% | 846,500 | 0.0% | 1.18% | +13.8% | |
| LPCN | Lipocine Inc | $4,622,000 | +31.2% | 669,921 | 0.0% | 1.06% | +9.8% | |
| ZSPH | ZS Pharma Inc | $4,208,000 | +1.2% | 100,000 | 0.0% | 0.97% | -15.3% | |
| OCRX | Ocera Therapeutics | $3,315,000 | -26.1% | 703,730 | 0.0% | 0.76% | -38.1% | |
| SNSS | Exit | Sunesis Pharmaceuticals | $0 | – | -536,189 | -100.0% | -0.38% | – |
| OHRP | Exit | OHR Pharmaceutical | $0 | – | -477,000 | -100.0% | -1.09% | – |
| Exit | Radius Health Inc | $0 | – | -233,294 | -100.0% | -2.50% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-05-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| DBV Technologies | 14 | Q4 2016 | 33.5% |
| BioCryst Pharmaceuticals Inc | 13 | Q4 2016 | 11.9% |
| Ocera Therapeutics | 13 | Q4 2016 | 4.9% |
| Anacor Pharmaceuticals Inc | 12 | Q1 2016 | 35.6% |
| Heron Therapeutics Inc | 12 | Q4 2016 | 20.5% |
| Flamel Technologies S.A. | 12 | Q4 2016 | 6.1% |
| GW Pharmaceuticals | 11 | Q4 2015 | 19.9% |
| Lipocine Inc | 11 | Q4 2016 | 7.5% |
| Stemline Therapeutics Inc | 11 | Q4 2016 | 1.7% |
| Zafgen Inc | 10 | Q3 2016 | 5.7% |
View VHCP Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2018-02-28 |
| 13F-HR | 2017-02-13 |
| 13F-HR | 2016-11-14 |
| 13F-HR | 2016-08-12 |
| 13F-HR | 2016-05-13 |
| 13F-HR | 2016-02-12 |
| 13F-HR | 2015-11-13 |
| 13F-HR | 2015-08-13 |
| 3 | 2015-06-17 |
| 13F-HR | 2015-05-14 |
View VHCP Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.